Literature DB >> 29713672

On and Off: A Dual Role for Cysteine Protease Autoprocessing of C difficile Toxin B on Cytotoxicity vs Proinflammatory Toxin Actions?

Xinhua Chen1, Ciaran P Kelly1.   

Abstract

Entities:  

Year:  2018        PMID: 29713672      PMCID: PMC5924747          DOI: 10.1016/j.jcmgh.2018.02.011

Source DB:  PubMed          Journal:  Cell Mol Gastroenterol Hepatol        ISSN: 2352-345X


× No keyword cloud information.
Clostridium difficile is the leading bacterial cause of health care–associated diarrhea in the developed world. In recent years, there has been an alarming increase in the incidence and severity of Clostridium difficile infections (CDIs), leading to increased academic, public health, and drug development research efforts on this bacterium. Two major virulence factors of C difficile are its toxin A (TcdA) and toxin B (TcdB). Understanding the mechanisms of action of these toxins is important to advance knowledge of CDI pathogenesis and identify new targets for prevention and therapy. TcdB, similar to TcdA, is a large single-chain protein that contains at least 4 distinct domains: the N-terminal glucosyltransferase enzymatic domain (GTD), cysteine protease enzyme domain (CPD), a putative translocation domain, and a C-terminal receptor binding domain. After receptor-mediated endocytosis and/or alternative entry pathways, the translocation domain mediates translocation of the CPD and GTD enzymatic regions into the cytosol where CPD self-cleaves in the presence of Inositol hexakisphosphate and releases GTD from the rest of the toxin. GTD inactivates Rho guanosine triphosphatases, which are key cell signaling molecules, leading to cytotoxicity. Thus, CPD plays a key role in the cytosolic delivery of GTD to turn on cytotoxicity. The proinflammatory activities of TcdB in human colon tissues and monocytes are well documented. Inactivation of RhoA results in the stimulation of the pyrin/apoptosis-associated speck-like protein containing a caspase recruitment domain inflammasome, which is one of the main signaling pathways used by these toxins to trigger the inflammatory response. However, the relationship between toxin’s cytotoxicity and proinflammatory activity has remained elusive. Although GTD-deficient toxins failed to induce acute intestinal responses in a number of studies,3, 4 indicating an essential role of GTD, there also have been reports suggesting that GTD is not required for the induced proinflammatory response of TcdB. In a new study in the current issue, Zhang et al made the novel and exciting observation that the CPD autoprocessing activity of TcdB acts as an off switch for proinflammatory activity and an on switch for cytotoxicity. By analyzing inflammatory responses in mouse ilea loops, human tissues, and immune cells, they found that blocking autoprocessing of TcdB by mutagenesis or chemical inhibition resulted in reduced cytotoxicity of the toxin, but surprisingly enhanced its proinflammatory activities in a ligated mouse ileal loop model. Zhang et al further validated in ex vivo human colonic tissues and immune cells that a noncleavable mutant TcdB was significantly more potent than the wild-type toxin in the induction of proinflammatory cytokines. This study suggests a dual role of CPD-mediated autoprocessing, which regulates the relative outcomes of cytotoxicity and proinflammatory induction. There have been suggestions that CPD inhibition could trap TcdB in the endosome, thereby mitigating cytotoxic effects. However, this study suggests that there may be an unintended consequence to CPD inhibition in the form of increased inflammatory pathway activation. The question remains, however, which of the 2 components, cytotoxicity or proinflammatory responses, contribute more to disease pathogenesis. The investigators showed that autocatalytic processing-deficient TcdA or TcdB mutants still have some cytotoxic activity, but at a reduced level compared with wild-type toxins. However, the proinflammatory activity was enhanced significantly. This may have alarming implications for drug development using CPD as targets. This study did not use infectious murine models of CDI, but it should be noted that in vivo studies in such models have found that CPD inhibitors reduced the overall severity of CDI.7, 8 Moreover, TcdB from hypervirulent C difficile shows increased autoprocessing efficiency. Although this study opens up many questions, it provides a new component of C difficile toxin mechanism of action, particularly in understanding how endosomal tethering, GTD domain localization, and/or release impact the inflammatory response. As such, it exposes a new and fascinating aspect to our understanding of the virulence of this difficult bacterium.
  8 in total

1.  A small-molecule antivirulence agent for treating Clostridium difficile infection.

Authors:  Kristina Oresic Bender; Megan Garland; Jessica A Ferreyra; Andrew J Hryckowian; Matthew A Child; Aaron W Puri; David E Solow-Cordero; Steven K Higginbottom; Ehud Segal; Niaz Banaei; Aimee Shen; Justin L Sonnenburg; Matthew Bogyo
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing.

Authors:  Jordi M Lanis; Logan D Hightower; Aimee Shen; Jimmy D Ballard
Journal:  Mol Microbiol       Date:  2012-02-28       Impact factor: 3.501

3.  Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome.

Authors:  Jeffrey Ng; Simon A Hirota; Olaf Gross; Yan Li; Annegret Ulke-Lemee; Mireille S Potentier; L Patrick Schenck; Akosua Vilaysane; Mark E Seamone; Hanping Feng; Glen D Armstrong; Jurg Tschopp; Justin A Macdonald; Daniel A Muruve; Paul L Beck
Journal:  Gastroenterology       Date:  2010-04-13       Impact factor: 22.682

4.  Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B.

Authors:  Ralf Gerhard; Swenja Queisser; Helma Tatge; Gesa Meyer; Oliver Dittrich-Breiholz; Michael Kracht; Hanping Feng; Ingo Just
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-26       Impact factor: 3.000

5.  Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins.

Authors:  Tor C Savidge; Petri Urvil; Numan Oezguen; Kausar Ali; Aproteem Choudhury; Vinay Acharya; Irina Pinchuk; Alfredo G Torres; Robert D English; John E Wiktorowicz; Michael Loeffelholz; Raj Kumar; Lianfa Shi; Weijia Nie; Werner Braun; Bo Herman; Alfred Hausladen; Hanping Feng; Jonathan S Stamler; Charalabos Pothoulakis
Journal:  Nat Med       Date:  2011-08-21       Impact factor: 53.440

6.  Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages.

Authors:  Xingmin Sun; Xiangyun He; Saul Tzipori; Ralf Gerhard; Hanping Feng
Journal:  Microb Pathog       Date:  2009-03-24       Impact factor: 3.738

7.  Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome.

Authors:  Hao Xu; Jieling Yang; Wenqing Gao; Lin Li; Peng Li; Li Zhang; Yi-Nan Gong; Xiaolan Peng; Jianzhong Jeff Xi; She Chen; Fengchao Wang; Feng Shao
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962

8.  Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins.

Authors:  Aimee Shen; Patrick J Lupardus; Malte M Gersch; Aaron W Puri; Victoria E Albrow; K Christopher Garcia; Matthew Bogyo
Journal:  Nat Struct Mol Biol       Date:  2011-02-13       Impact factor: 15.369

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.